title: Why meperidine should not make a comeback in treating patients with sickle cell disease.
authors.affiliation: St. John's University College of Pharmacy, New York University School of Medicine, New York City Poison Control Center, Bellevue Hospital's Emergency Department, Queens, NY, USA. MHowlandNY@aol.com
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Howland
authors.forename: Lewis R
authors.initials: LR
authors.lastname: Goldfrank
mesh_terms: D000701:Analgesics, Opioid / Q000378:metabolism / Q000627:therapeutic use*; D000755:Anemia, Sickle Cell / Q000150:complications*; D006801:Humans; D008614:Meperidine / Q000378:metabolism / Q000627:therapeutic use*; D010146:Pain / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000701:Analgesics, Opioid; D008614:Meperidine